Cancers such as melanoma have long latent periods during which cancer cells are dormant and difficult to detect. These dormant cells are typically resistant to therapy when they re-enter the cell cycle. To improve patient outcomes, scientists search for new dormant cancer cell biomarkers that can support personalized therapy development. However, because the dormant stage can last longer than a decade, it is difficult to obtain longitudinal patient samples that permit proper characterization of a cancer’s evolution.
Download this case study from Thermo Fisher Scientific to learn how researchers and clinicians built a biobank that supports rapid personalized therapy development for cancer patients.